The U.S. Supreme Court declined to hear multiple lawsuits challenging Medicare’s drug price negotiation program under the Inflation Reduction Act (IRA), dealing another procedural setback to the brand drug industry. The justices refused cert petitions involving AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Novo Nordisk. The decision follows losses for the companies in lower courts and leaves the IRA negotiation framework in place without a merits review. Analysts had anticipated limited odds given the absence of a circuit split and the Supreme Court’s general practice of declining when lower courts agree.